Home > Browse Issues > Vol.30 No.5
Study in Targeting to Cyclin B1 against Malignant Tumors
Ling Zhang1,2, Ri-Shu Chen3, Tao Zhang1*, Ji-Cheng Li2
1Department of Oncology, General Hospital of Chengdu Military Command of PLA, Chengdu 610083, China; 2Institute of Cell Biology, Zhejiang University, Hangzhou 310058, China; 3Zhejiang Yueqing Second Hospital, Yueqing 32560
Abstract: Cyclin B1 (CCNB1) is the regulatory subunit of the cdc2 serine/threonine kinase (mitotic promoting factor， MPF)， and accumulation of CCNB1 in late G2 phase of the cell cycle is a prerequisite for mitotic initiation in mammalian cells. In addition， CCNB1 is overexpressed in various tumor types and plays important roles in cancer development， and was identified a new tumor antigen. Therefore， a potential strategy for cancer gene therapy is to suppress the expression and/or activity of CCNB1 by various methods. This paper reviews the recent advances of anti-tumor research in the field of inhibitting CCNB1.
CN
EN